Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis

European Neurology

Volumn 54, Issue 1, 2005, Pages 28-33

  Zingler, Vera Carina ^a,b   Näbauer, Michael ^a   Jahn, Klaus ^a   Groß, Ariane ^a   Hohlfeld, Reinhard ^a   Brandt, Thomas ^a   Strupp, Michael ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cardiomyopathy; Cardiotoxicity; Echocardiogram; Ejection fraction; Mitoxantrone; Multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; AGED; ANAMNESIS; ARTICLE; CALCULATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; HEART; HEART DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS;

EID: 24944493605     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087242     Document Type: Article

References (34)

1. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
2. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
3. Noseworthy JH, Hopkins MB, Vandervoort MK, Karlik SJ, Lee DH, Penman M, et al: An open trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 1993;43:1401-1406.
4. Gonsette RE, Demonty L: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990;40(suppl 1):261.
5. Kappos L, Gold R, Künstler E, et al: Mitoxantrone in the treatment of rapidly progressive MS: A pilot study with serial gadolinium-enhanced MRI (abstract). Neurology 1990;40(suppl 1):261.
6. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW: The use of mitoxantrone (novantrone) for the treatment of multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2003;61:1332-1338.
7. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE: Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003;9:59-62.
8. Herman EH, Zhang J, Hasinoff BB, Clark JR, Ferrans VJ: Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol 1997;29:2415-2430.
9. Dukart G, Barone JS: An overview of cardiac episodes following mitoxantrone administration. Cancer Treat Symp 1984;3:35-41.
10. Foster BJ, Lev K, Bergemann C, et al: Cardiac advents in Phase II trials with mitoxantrone. Cancer Treat Symp 1984;3:43-46.
11. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K: Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985;3:123-132.
12. Mather FJ, Simon RM, Clark GM, Von Hoff DD: Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group Phase II studies. Cancer Treat Rep 1987;71:609-613.
13. Hartung HP, Gonsette R, Morrissey S, Krapf H, Fazekas F: Mitoxanrone; in Rudick RA, Goodkin DE (eds): Multiple Sclerosis Therapeutics. London, Martin Dunitz 1999, pp 335-348.
14. Edan G, Brochet B, Clanet M, et al: Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult Scler 2001;7(suppl 1): S14.
15. Mauch E, Eisenmann S, Hahn A, et al: Mitoxantrone (MITOX) in the treatment of patients with multiple sclerosis (MS): A large single center experience (abstract). American Neurological Association, 1999.
16. Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H: Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 1992;242:96-102.
17. De Castro S, Cartoni D, Millefiorini E, Funaro S, Gasperini C, Morino S, et al: Noninvasive assessment of mitoxantrone in cardiotoxicity in relapsing-remitting multiple sclerosis. J Clin Pharmacol 1995;35:627-632.
18. Strotmann JM, Spindler M, Weilbach FX, Gold R, Ertl G, Voelker W: Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am J Cardiol 2002;89:1222-1225.
19. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
20. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al: Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
21. Kurtzke JF: Rating neurological impairment in multiple sclerosis: An expanded disability status scale(EDSS). Neurology 1983;33:1444-1452.
22. Voltz R, Starck M, Zingler VC, Strupp M: Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004;10:472-474.
23. Teichholz LE, Kreulen T, Herman MV, Gorlin R: Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976;37:7-11.
24. Kronik G, Slany J, Mosslacher H: Comparative value of eight M-mode echocardiographic formulas for determiningleft ventricular stroke volume. A correlative study with thermodilution and left ventricular single-plane cineangiography. Circulation 1979;60:1308-1316.
25. Zingler VC, Strupp M, Jalm K, Gross A, Hohlfeld R, Brandt T: The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. Nervenarzt 2005;76:740-747.
26. Gonsette RE: Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 2003;206:203-208.
27. Millefiorini E, Gasperini C, Pozzilli C, et al: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
28. Zephir H, de Seze J, Duhamel A, et al: Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004;218:73-77.
29. Yudkin PL, Ellison GW, Ghezzi A, et al: Overview of azathioprine therapy in multiple sclerosis. Lancet 1993;338:1051-1055.
30. Athanasiou T, Al-Ruzzeh S, Del Stanbridge R, Casula RP, Glenville BE, Amrani M: Is the female gender an independent predictor of adverse outcome after off-pump coronary artery bypass grafting? Ann Thorac Surg 2003;75:1153-1160.
31. Koch CG, Mangano CM, Schwann N, Vaccarino V: Is it gender, methodology, or something else? J Thorac Cardiovasc Surg 2003;126:932-935.
32. Ruel M, Bianchi C, Khan TA, Xu S, Liddicoat JR, Voisine P, et al: Gene expression profile after cardiopulmonary bypass and cardioplegic arrest. J Thorac Cardiovasc Surg 2003;126:1521-1530.
33. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenmann S, Hartung HP, et al: Cardiac adverse effects associated with mitoxantrone (novantrone) therapy in patients with MS. Neurology 2002;59:909-913.
34. Goffette S, van Pesch V, Sindic CJM: Severe delayed heart failure in three MS patients previously treated with mitoxantrone. Mult Scler 2004;10(suppl 2):S269.